Context Therapeutics Inc (CNTX)
2.15
+0.01
(+0.47%)
USD |
NASDAQ |
Jun 25, 16:00
2.15
0.00 (0.00%)
After-Hours: 20:00
Context Therapeutics Research and Development Expense (Annual): 17.78M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 17.78M |
| December 31, 2022 | 7.091M |
| December 31, 2021 | 3.805M |
| Date | Value |
|---|---|
| December 31, 2020 | 1.642M |
| December 31, 2019 | 2.412M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
1.642M
Minimum
2020
17.78M
Maximum
2023
6.546M
Average
3.805M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Emergent BioSolutions Inc | 111.40M |
| AbbVie Inc | 7.675B |
| Revance Therapeutics Inc | 79.41M |
| Design Therapeutics Inc | 57.06M |
| NovaBay Pharmaceuticals Inc | 0.068M |